-- Online-First Publication Currently Available -- -- First Randomized Trial With Survival Endpoint in Second-Line Myelodysplastic Syndromes (MDS) -- -- New Phase 3 "INSPIRE" Study of IV Rigosertib Currently Enrolling Patients -- NEWTOWN, Pa., March 09, 2016 (GLOBE NEWSWIRE) -- Onconova
NEWTOWN, Pa., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it received a positive determination from the NASDAQ Stock Market granting
NEWTOWN, Pa., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the Company will host a Key Opinion Leader breakfast focused on the
--Combination Achieved 77% Overall Response Rate in all MDS Patients-- --Overall Response Rate of 84% in treatment-naïve MDS Patients-- --Response Rate of 64% in MDS Patients who had Previously Failed HMAs-- --Company to Provide Further Information on Next Steps for Combination Development
NEWTOWN, Pa., Nov. 25, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Ramesh Kumar, Ph.D., President and Chief Executive Officer, will
NEWTOWN, Pa., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the third quarter ended
NEWTOWN, Pa., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of new non-clinical data for two of the Company's proprietary
NEWTOWN, Pa., Oct. 08, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the Company has entered into a share purchase agreement and a registration
